CO2023005611A2 - Anticuerpos anti-cd47 novedosos y usos de los mismos - Google Patents

Anticuerpos anti-cd47 novedosos y usos de los mismos

Info

Publication number
CO2023005611A2
CO2023005611A2 CONC2023/0005611A CO2023005611A CO2023005611A2 CO 2023005611 A2 CO2023005611 A2 CO 2023005611A2 CO 2023005611 A CO2023005611 A CO 2023005611A CO 2023005611 A2 CO2023005611 A2 CO 2023005611A2
Authority
CO
Colombia
Prior art keywords
antibodies
novel anti
hemagglutination
humans
therapeutic agent
Prior art date
Application number
CONC2023/0005611A
Other languages
English (en)
Inventor
Zhengyi Wang
Wei Cao
Bingshi Guo
Cong Xu
Original Assignee
I Mab Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Co Ltd filed Critical I Mab Biopharma Co Ltd
Publication of CO2023005611A2 publication Critical patent/CO2023005611A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en el presente documento anticuerpos CD47 y fragmentos inmunológicamente activos de los mismos que tienen baja inmunogenicidad en humanos y provocan un nivel bajo o nulo de agotamiento de glóbulos rojos o hemoaglutinación. También se proporcionan composiciones farmacéuticas que contienen dichos anticuerpos o fragmentos de anticuerpos, así como métodos de tratamiento utilizando dichos anticuerpos, por ejemplo, como agentes únicos o en combinación con otro(s) agente(s) terapéutico(s).
CONC2023/0005611A 2020-10-14 2023-05-02 Anticuerpos anti-cd47 novedosos y usos de los mismos CO2023005611A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020120869 2020-10-14
CN2020122188 2020-10-20
PCT/CN2021/123892 WO2022078465A1 (en) 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2023005611A2 true CO2023005611A2 (es) 2023-05-29

Family

ID=81207683

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0005611A CO2023005611A2 (es) 2020-10-14 2023-05-02 Anticuerpos anti-cd47 novedosos y usos de los mismos

Country Status (12)

Country Link
US (1) US20230399400A1 (es)
EP (1) EP4229088A1 (es)
JP (1) JP2023546277A (es)
KR (1) KR20230114745A (es)
CN (1) CN116348601A (es)
AU (1) AU2021360633A1 (es)
CA (1) CA3198895A1 (es)
CO (1) CO2023005611A2 (es)
IL (1) IL302112A (es)
MX (1) MX2023004223A (es)
TW (1) TW202229351A (es)
WO (1) WO2022078465A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220104298A (ko) 2016-10-20 2022-07-26 아이-맵 바이오파마 유에스 리미티드 새로운 cd47 단일클론 항체 및 그 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220104298A (ko) * 2016-10-20 2022-07-26 아이-맵 바이오파마 유에스 리미티드 새로운 cd47 단일클론 항체 및 그 용도
AU2018363479B2 (en) * 2017-11-10 2021-09-16 I-Mab Biopharma Us Limited Fusion proteins containing CD47 antibodies and cytokines
KR20210098427A (ko) * 2018-10-31 2021-08-10 아이-맵 바이오파마 유에스 리미티드 신규한 ｃｄ47 항체 및 이의 사용방법
CA3097443A1 (en) * 2018-11-12 2020-05-22 I-Mab Biopharma Us Limited Fusion proteins containing cd47 antibodies and cytokines

Also Published As

Publication number Publication date
US20230399400A1 (en) 2023-12-14
MX2023004223A (es) 2023-08-03
IL302112A (en) 2023-06-01
EP4229088A1 (en) 2023-08-23
TW202229351A (zh) 2022-08-01
CN116348601A (zh) 2023-06-27
JP2023546277A (ja) 2023-11-01
KR20230114745A (ko) 2023-08-01
WO2022078465A1 (en) 2022-04-21
CA3198895A1 (en) 2022-04-21
AU2021360633A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
CO2019005033A2 (es) Anticuerpos monoclonales cd47 novedosos y usos de los mismos
CL2022003085A1 (es) Anticuerpos contra sars-cov-2
CO2020001960A2 (es) Formulaciones de anticuerpos anti-c5 de alta concentración
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
CO2023005611A2 (es) Anticuerpos anti-cd47 novedosos y usos de los mismos
CO2021003931A2 (es) Dosis unitaria de vacuna contra el dengue y administración de esta
CO6751277A2 (es) Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes
BR112017023380A2 (pt) sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo.
Kashiwagi et al. Near-infrared laser adjuvant for influenza vaccine
BR112018008684A2 (pt) formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
ECSP044933A (es) Método y montaje para aumentar el volumen del cabello
CY1109286T1 (el) Σκευασμα τυπου φυραματος που περιλαμβανουν διοξειδιο πυριτιου
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
DOP2015000162A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos
CO2023002959A2 (es) Neoantígenos ras y usos de los mismos
CO2022007361A2 (es) Terapia de combinación para el tratamiento de cáncer cerebral
UY39464A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
CL2020000508A1 (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.
CO2024003578A2 (es) Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
BR112021023319A2 (pt) Vetor viral
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
AR106978A1 (es) Vacunas felinas de núcleo híbrido